Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.

Autor:	Healy BC; Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA/ Department of Neurology, Harvard Medical School, Boston, MA, USA/ Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA., Zurawski J; Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA/ Department of Neurology, Harvard Medical School, Boston, MA, USA., Gonzalez CT; Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA., Chitnis T; Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA/ Department of Neurology, Harvard Medical School, Boston, MA, USA., Weiner HL; Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA/ Department of Neurology, Harvard Medical School, Boston, MA, USA., Glanz BI; Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA/ Department of Neurology, Harvard Medical School, Boston, MA, USA/ Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.
Jazyk:	angličtina
Zdroj:	Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2019 Nov; Vol. 25 (13), pp. 1791-1799. Date of Electronic Publication: 2018 Nov 01.
DOI:	10.1177/1352458518810159
Abstrakt:	Background: To date, the computerized adaptive testing (CAT) version of the Neuro-quality of life (QOL) has not been assessed in a large sample of people with multiple sclerosis (MS). Objective: The aim of this study was to assess the associations between the CAT version of Neuro-QOL and other clinical and patient-reported outcome measures. Methods: Subjects ( n  = 364) enrolled in SysteMS completed the CAT version of the Neuro-QOL and the 36-Item Short Form Survey (SF-36) within 4 weeks of a clinical exam that included the Multiple Sclerosis Functional Composite-4 (MSFC-4). The correlations between the Neuro-QOL domains and the MSFC-4 subscores and the SF-36 scores were calculated. The changes over time in the Neuro-QOL and other measures were also examined. Results: The lower extremity functioning score of the Neuro-QOL showed the highest correlations with MSFC-4 components including Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive score. The expected domains of the Neuro-QOL showed high correlations with the SF-36 subscores, and some Neuro-QOL domains were associated with many SF-36 subscores. There was limited longitudinal change on the Neuro-QOL domains over 12 months, and the change was not associated with change on other measures. Conclusion: The CAT version of the Neuro-QOL shows many of the expected associations with clinical and patient-reported outcome measures.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu